5F-AKB48

5F-AKB48 inhibits hERG potassium channels at a physiologically relevant concentration (IC50 2.16 µM) via a noncanonical binding site. In individuals with pre-existing cardiac conduction abnormalities or long QT syndrome, this creates potentially fatal risk of QT prolongation and torsades de pointes.

A case of non-fatal myocardial infarction was reported in a young man following smoking of 5F-APINACA, with chest pain onset approximately 4 hours post-inhalation. Pre-existing coronary artery disease or ischemic heart disease significantly elevates the risk of acute cardiovascular events.

Co-application of 5F-AKB48 with the antipsychotic olanzapine produces additive hERG inhibition in patch-clamp experiments. By mechanistic extension, concurrent use of any QT-prolonging medication represents a risk for torsades de pointes. This is particularly relevant in clinical settings where antipsychotics may be administered to manage SCRA-induced agitation.

The WHO ECDD review documents seizures among the high-dose adverse effects of 5F-AKB48. Individuals with pre-existing epilepsy or other seizure disorders face increased risk of convulsive events, particularly at higher doses where the margin between desired and dangerous effects is narrow.

Pre-existing psychotic disorders (schizophrenia, schizoaffective disorder) or history of first-episode psychosis represent significant risk factors. SCRAs including 5F-AKB48 are documented to precipitate acute psychosis, paranoid states, and delusions, particularly at higher doses. The dose-dependent anxiogenic shift from full CB1 agonism makes psychiatric decompensation unpredictable.

5F-AKB48 is primarily metabolized by CYP3A4 with contributions from CYP2C8, CYP2C19, and CYP2D6. Significant hepatic impairment would reduce metabolic clearance, elevating systemic exposure and prolonging both desired and toxic effects. The active metabolite 4OH-5F-AKB48 also requires hepatic metabolism for formation and clearance.

The synthetic cannabinoid class is associated with acute kidney injury including rhabdomyolysis-induced renal failure. Pre-existing renal impairment both increases vulnerability to AKI and reduces clearance of 5F-AKB48 and its active metabolites, potentially prolonging toxic exposure.

No reproductive toxicology, teratogenicity, or lactation transfer data exist for 5F-AKB48. Given full CB1 receptor agonism and the established role of the endocannabinoid system in fetal neurodevelopment, exposure during pregnancy or lactation is contraindicated on a precautionary basis.